You may have heard of GLP-1s, a class of medications that boost weight loss by curbing appetite, slowing digestion, and reducing cravings
They also highlight a recurring pattern in peptide drug development: early safety signals, particularly those observed at supraphysiologic exposure levels or in non-human models, have frequently led to premature abandonment of otherwise biologically compelling targets
Landmark: Orforglipron (Eli Lilly, approved April 2026) is the first oral non-peptide GLP-1R agonist approved globally a structural breakthrough that removes the cold-chain, injection, and adherence barriers that have constrained the class
When evaluating retatrutide research data, the safety profile appears manageable and consistent with the GLP-1/GIP/glucagon receptor agonist class
- Curso sobre el Estudio y Tratamiento de la Disfuncin Temporomandibular por la Fundaci Universitria del Bages